One in Four Patients in Latest Clinical Study Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment
13 juil. 2021 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Independent Study Shows 97 Percent of Vivos Patients Achieved Their Desired Treatment Outcome
07 juil. 2021 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Founder & Chief Medical Officer Releases New Book Highlighting His Groundbreaking Work
26 mai 2021 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update
17 mai 2021 16h05 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Schedules First Quarter 2021 Financial Results Conference Call
13 mai 2021 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 13, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative...
Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
11 mai 2021 16h29 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative...
Vivos Therapeutics Announces Pricing of $24 Million Follow-On Offering
06 mai 2021 21h41 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative...
Vivos Therapeutics Announces Integrative Cardiologist Dr. Mimi Guarneri as New Medical Director of Clinical Education
14 avr. 2021 09h15 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., April 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative...
Vivos Therapeutics to Participate at the Emerging Growth Conference
12 avr. 2021 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., April 12, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative...
Vivos Therapeutics to Launch MyoCorrect Orofacial Myofunctional Therapy Service
30 mars 2021 08h00 HE
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., March 30, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...